10x Genomics (NASDAQ:TXG) Receives $13.54 Consensus Target Price from Analysts

Shares of 10x Genomics (NASDAQ:TXG) have received an average recommendation of “Hold” from the fifteen brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $13.6538.

A number of equities analysts have commented on TXG shares. Bank of America raised their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Thursday, June 26th. UBS Group lifted their price target on 10x Genomics from $12.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Piper Sandler began coverage on 10x Genomics in a research note on Thursday. They issued a “neutral” rating and a $15.00 price target on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research note on Saturday, August 30th. Finally, Wall Street Zen lowered 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday.

10x Genomics Price Performance

10x Genomics stock opened at $12.64 on Friday. The stock’s fifty day moving average price is $13.21 and its two-hundred day moving average price is $10.81. 10x Genomics has a one year low of $6.78 and a one year high of $24.38. The firm has a market cap of $1.57 billion, a PE ratio of -18.06 and a beta of 2.00.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The firm had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. During the same quarter last year, the company earned ($0.32) EPS. The company’s revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. Sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer directly owned 309,273 shares of the company’s stock, valued at approximately $4,264,874.67. The trade was a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider directly owned 440,888 shares in the company, valued at $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 39,149 shares of company stock worth $539,865 in the last 90 days. Insiders own 9.39% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Orion Porfolio Solutions LLC acquired a new position in shares of 10x Genomics in the 2nd quarter valued at about $158,000. Nikko Asset Management Americas Inc. lifted its stake in shares of 10x Genomics by 12.1% in the 2nd quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock valued at $69,532,000 after purchasing an additional 646,997 shares during the period. CANADA LIFE ASSURANCE Co lifted its stake in shares of 10x Genomics by 167.9% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 22,069 shares of the company’s stock valued at $256,000 after purchasing an additional 13,831 shares during the period. Exome Asset Management LLC acquired a new position in shares of 10x Genomics in the 2nd quarter valued at about $1,895,000. Finally, Corient Private Wealth LLC acquired a new position in shares of 10x Genomics in the 2nd quarter valued at about $597,000. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.